Quest Diagnostics Inc Stock Price, News & Analysis

On January 17, 2023, Quest Diagnostics (NYSE: DGX) announced plans for Pack Health to nearly double its headquarters in Birmingham, Alabama, creating at least 200 new full-time jobs. This expansion, supported by state and local economic incentives, is expected to generate an estimated $27 million in economic impact over the next 20 years. The new facility will enhance Pack Health's capabilities in providing digital health coaching and chronic condition management, vital for improving patient outcomes. This marks a year since Quest's acquisition of Pack Health, emphasizing its role in connecting diagnostic insights to actionable health improvements.

Quest Diagnostics has partnered with the American Heart Association (AHA) to address significant health disparities affecting Native Americans, particularly in heart disease, stroke, and diabetes. Since 2021, the Quest Diagnostics Foundation has funded AHA initiatives at Federally Qualified Health Centers (FQHCs) across six states, aiming to provide essential resources for hypertension and COVID-19.

The AHA's programs, supported by a Quest grant, focus on delivering effective high blood pressure resources to under-resourced communities severely impacted by the pandemic. This collaboration aims to improve health outcomes in multiple indigenous health centers.

Quest Diagnostics has awarded a grant to ConferMED, enhancing access to specialty care for underserved communities. The funding supports ConferMED's eConsult platform, connecting primary care providers in five U.S. regions with specialists. This initiative aims to address health inequities by providing virtual consultations at Federally Qualified Health Centers (FQHCs), impacting over 475,000 patients. The grant covers the full implementation cost and two years of services, improving chronic disease outcomes and reducing unnecessary hospital visits.

Quest Diagnostics announced partnerships aimed at facilitating safe participation in recreational activities post-COVID-19 pandemic. Key initiatives include acting as the sole on-site testing provider for the historic Boston Marathon, partnering with Carnival and Royal Caribbean for pre-cruise COVID-19 testing, and managing testing at the BNP Paribas Tennis Open. These efforts underscore Quest's commitment to health and safety during public events, helping to streamline testing procedures across various sectors.

Quest Diagnostics has launched multiple initiatives to support in-school COVID-19 testing, emphasizing the importance of safe classroom environments for children impacted by the pandemic. Key programs include the "Back to the Classroom" initiative, which focuses on K-12 testing solutions, partnerships with biotechnology firm Ginkgo Bioworks, and collaborations with various state health departments. Additionally, testing access is being expanded through partnerships with Battelle Memorial Institute to serve underserved populations. These efforts aim to facilitate safe educational settings for students, faculty, and staff.

Quest Diagnostics participated in the 8th annual I-HEAL Community Wellness Day in the Mississippi Delta, providing no-cost health screenings to approximately 80 attendees. The event, hosted by the Glenn Family Foundation, saw over 700 participants receive healthy food, flu shots, and health resources. Stacey Ingram from Quest emphasized the importance of the event in improving community health outcomes. The foundation has previously assisted over 7,000 food-insecure children and implemented health literacy programs, showcasing a robust commitment to community health improvement.

Quest Diagnostics (NYSE: DGX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. Eastern Time. CEO Jim Davis and CFO Sam Samad will discuss the company's performance, strategy, and market trends. The live presentation will be webcast and available on their investor relations page. An archived version will be accessible within 24 hours and remain available until February 10, 2023.

Quest Diagnostics aims to empower individuals to enhance health outcomes through diagnostic insights.

Quest Diagnostics' latest Health Trends report reveals significant issues regarding drug misuse in the U.S. based on over 20 million drug tests conducted over the past decade. In 2021, 49% of individuals tested showed evidence of prescription drug misuse. Alarmingly, polysubstance use increased to 52%, up from 33% in 2012, while amphetamine use surged 5-fold, affecting 9.2% of those tested. The report emphasizes the ongoing risk of drug misuse across various age groups, particularly among younger adults, highlighting a pressing need for early intervention and preventive care.

Quest Diagnostics (NYSE: DGX) announced a strategic laboratory collaboration with Northern Light Health to acquire its outreach laboratory business and manage nine hospital laboratories in Maine. The agreement, selected after a competitive bid, is an all-cash transaction aimed at enhancing access to diagnostic services. The collaboration will leverage Quest's advanced testing capabilities, improving patient affordability and care in the region. Completion of the deal is expected in Q1 2023, although financial details remain undisclosed.